GILD — Gilead Sciences
Data coverage, completeness and provenance for Gilead Sciences in the Stock Market API — Health Care · Drug Manufacturers - General.
Stored price coverage
Source date: 2026-11-19T21:00:01. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-11-19 | 166.5300 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-18 | 168.9800 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-17 | 170.2600 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-16 | 167.5800 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-13 | 168.0800 | USD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/GILD/prices · Price parameters and adjustment semantics
No archived filings are currently stored for this listing.
Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Employees: 17,000 · Website: https://www.gilead.com · Profile fields populated: 75%
Data completeness by statement
Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/GILD/financials.
Financial statement coverage (USD)
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2025 (USD) | 2025-12-31 | 32 | sec_edgar | ||||
| FY2024 (USD) | 2024-12-31 | 32 | sec_edgar | ||||
| FY2023 (USD) | 2023-12-31 | 32 | sec_edgar | ||||
| FY2022 (USD) | 2022-12-31 | 32 | sec_edgar | ||||
| FY2021 (USD) | 2021-12-31 | 32 | sec_edgar |
Get GILD data via the API
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Company profile
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/GILD
Financial statements
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/GILD/financials
Computed ratios
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/GILD/metrics/summary
News & announcements
Dated press releases and announcements with source links.
GET /api/v1/companies/GILD/news
Quick start
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/GILD
Query GILD programmatically
Free tier — instant API key. Built for AI agents.
Other NASDAQ · Health Care companies covered
Frequently Asked Questions
- What data does the API provide for GILD?
- Stored coverage for GILD: price data available, financial statements available, 0 archived filings. REST endpoints are under /api/v1/companies/GILD; inspect available source metadata for provenance.
- How complete is GILD's financial data?
- The anchor reporting period (FY2025) has 100.0% of the 17 core statement fields populated. Primary source: sec_edgar.
- What reporting periods are covered for GILD?
- 5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/GILD/financials.
- Where does GILD's data come from?
- Stored price source: yfinance. Primary source for the statement snapshot: sec_edgar. Inspect available period and field source tags at /api/v1/companies/GILD/financials; missing tags do not establish provenance.